Increased chemerin and decreased omentin-1 levels in morbidly obese patients are correlated with insulin resistance, oxidative stress and chronic inflammation

Clujul Medical

Volumn 87, Issue 1, 2014, Pages 19-26

  Cătoi, Adriana Florinela ^a   Suciu, Şoimiţa ^a   Pârvu, Alina Elena ^a   Copăescu, Cătălin ^b   Galea, Romeo Florin ^a   Buzoianu, Anca Dana ^a   Vereşiu, Ioan Andrei ^a   Cătoi, Cornel ^c   Pop, Ioana Delia ^c  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Bariatric Center of Excellence (BariXL) Ponderas (Delta) Hospital   (Romania)

^c UNIVERSITY OF AGRICULTURAL SCIENCES AND VETERINARY MEDICINE   (Romania)

Author keywords

Adipokines; Chronic inflammation; Morbid obesity; Oxidative stress

Indexed keywords

EID: 84914099276     PISSN: 12222119     EISSN: 20668872     Source Type: Journal    
DOI: 10.15386/cjm.2014.8872.871.afc1     Document Type: Article

References (43)

1. Buchwald H, Avidor Y, Braunwald E et al. Bariatric Surgery A Systematic Review and Meta-analysis. JAMA, 2004; 292:1724-1737.
2. Bulló M, Casas-Agustench P, Amigó-Correig P, Aranceta J, Salas-Salvadó J. Inflammation, obesity and comorbidities: the role of diet. Public Health Nutrition, 2007; 10(10A):1164-1172.
3. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol, 2010; 314:1-16.
4. Fernández-Sánchez A, Madrigal-Santillán E, Bautista M et al. Inflammation, Oxidative Stress, and Obesity. Int J Mol Sci, 2011; 12:3117-3132.
5. Wang Z, Nakayama T. Inflammation, a Link between Obesity and Cardiovascular Disease. Hindawi Publishing Corporation Mediators of Inflammation, 2010; ID 535918:1-17.
6. John H, Hierer J, Haas O, Forssmann WG. Quantification of angiotensin-converting-enzymemediated degradation of human chemerin 145-154 in plasma by matrix-assisted laser desorption/ionization-timeof- flight mass spectrometry. Anal Biochem. 2007; 362(1):117-125.
7. Rourke JL, Dranse HJ, Sinal CJ. Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes Rev, 2013;14(3):245-262.
8. Roman AA, Parlee SD, Sinal CJ. Chemerin: a potential endocrine link between obesity and type 2 diabetes. Endocrine, 2012; 42:243-251.
9. Tan BK, Chen J, Farhatullah S et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes, 2009; 58:1971-1977.
10. Lehrke M, Becker A, Greif M et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol, 2009;161(2):339-344.
11. Wang LY, Wei L, Yu HY et al. Relationship of serum Chemerin to obesity and type 2 diabetes mellitus. Zhonghua Yi Xue Za Zhi, 2009; 89(4):235-238.
12. Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population-a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2008; 152(2):217-221.
13. Singh B, Arora S, B. Goswami B, Mallika V. Metabolic syndrome: A review of emerging markers and management. Diabetes & Metabolic Syndrome:Clinical Research & Reviews, 2009; 3(4):240-254.
14. Zhuang XF, Zhao MM, Weng CL, Sun NL. Adipocytokines: A bridge connecting obesity and insulin resistance. Med Hypotheses, 2009; 73(6):981-985.
15. de Souza Batista CM, Yang RZ, Lee MJ et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 2007; 56(6):1655-1661.
16. Tan BK, Adya R, Randeva HS. Omentin: A Novel Link Between Inflammation, Diabesity, and Cardiovascular Disease. Trends Cardiovasc Med, 2010; 20:143-148.
17. Bozaoglu K, Bolton K, McMillan J et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology, 2007; 148(10):4687-4694.
18. Sell H, Divoux A, Poitou C et al. Chemerin Correlates with Markers for Fatty Liver in Morbidly Obese Patients and Strongly Decreases after Weight Loss Induced by Bariatric Surgery. J Clin Endocrinol Metab, 2010; 95(6):2892-2896.
19. Sledzinski T, Korczynska J, Hallmann A et al. The increase of serum chemerin concentration is mainly associated with the increase of BMI in obese, non-diabetic subjects. J Endocrinol Invest, 2013; 36(6):428-434.
20. Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract, 2010; 88(1):29-33.
21. Weigert J, Neumeier M, Wanninger J et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf), 2010;72(3):342-348.
22. Chakaroun R, Raschpichler M, Klöting N et al. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism, 2012; 61(5):706-714.
23. Gürsoy G, Ki{dotless}rnap, NG, Eşbah O et al. The relationship between plasma omentin-1 levels and insulin resistance in newly diagnosed type 2 diabeti{dotless}c women. Clinical Reviews and Opinions, 2010; 2(4):49-54.
24. Yan P, Liu D, Long M, Ren Y, Pang J, Li R. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes, 2011; 119(4):257-263.
25. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001; 79(4):373-374.
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative centrifuge. Clin Chem, 1972; 18:499-500.
27. Mattheus DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessement:insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28(7):412-419.
28. Ghasemi A, Hedayati M, Biabani H. Protein precipitation methods evaluated for determination of serum nitric oxide end products by the Griess assay. J Med Sci Res, 2007; 2:29-32.
29. Miranda K, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide, 2001; 5(1):62-71.
30. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem, 2005; 38(12):1103-1111.
31. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem, 2004; 37(2):112-119.
32. Harma M, Harma M, Erel O. Increased oxidative stress in patients with hydatidiform mole. Swiss Med Wkly, 2003; 133(41-42):563-566.
33. Cătoi AF, Pârvu A, Galea RF, Pop ID, Mureşan A, Cătoi C. Nitric Oxide, Oxidant Status and Antioxidant Response in Morbidly Obese Patients: the Impact of 1-Year Surgical Weight Loss. Obesity Surgery, 2013; 23:1858-1863.
34. Hopps E, Not o D, Caimi G, Averna MR. A novel component of the metabolic syndrome: The oxidative stress. Nutrition, Metabolism and Cardiovascular Diseases 2010;20:72-77.
35. Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab, 2013; 98(3):E514-E517.
36. Bozaoglu K, Segal D, Shields KA. et al. Chemerin Is Associated with Metabolic Syndrome Phenotypes in a Mexican-American Population. J Clin Endocrinol Metab, 2009; 94(8):3085-3088.
37. Shan YU, Ying Z, Mei-zhen L et al. Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients. Chinese Medical Journal, 2012; 125(19):3440-3444.
38. Neuparth MJ, Proença JB, Santos-Silva A, Coimbra S. Adipokines, Oxidized Low-Density Lipoprotein, and C-Reactive Protein Levels in Lean, Overweight, and Obese Portuguese Patients with Type 2 Diabetes. Hindawi Publishing Corporation ISRN Obesity, 2013; ID 142097;1-7.
39. Fatima S, Bozaoglu K, Rehman R, Alam F, Memon AS. Elevated Chemerin Levels in Pakistani Men: An Interrelation with Metabolic Syndrome Phenotypes. PLOS ONE, 2013;8(2):1-7.
40. Auguet T, Quintero Y, Riesco D et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Medical Genetics, 2011; 12:60.
41. Moreno-Navarrete JM, Catalán V, Ortega F et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010; 7:27. doi: 10.1186/1743-7075-7-27.
42. El-Mesallamy HO, El-Derany MO, Hamd NM. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med, 2011; 28(10):1194-1200. doi: 10.1111/j.1464-5491.2011.03353.x.
43. Moreno-Navarrete JM, Francisco Ortega F, Castro A, Sabater M, Ricart W, Fernández-Real JM. Circulating Omentin as a Novel Biomarker of Endothelial Dysfunction. Obesity Journal, 2011; 19(8):1552-1559.